SCHEMBL2284795

SCHEMBL2284795

O=C(O)CN(CCN(CC(=O)O)Cc1ccccc1)CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.56
▸ EYA2 O00167 1/20 0.56
▸ APP P05067 1/20 0.56
▸ ACE P12821 1/20 0.56
▸ LMNA P02545 2/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ CHRM2 P08172 1/20 0.54
▸ ADRA2A P08913 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ DRD1 P21728 1/20 0.54
▸ SLC6A2 P23975 1/20 0.54
▸ SLC6A4 P31645 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ ADRA1A P35348 1/20 0.54
▸ DRD3 P35462 1/20 0.54
▸ BLM P54132 1/20 0.54
▸ PMP22 Q01453 1/20 0.54
▸ SLC6A3 Q01959 1/20 0.54
▸ HRH3 Q9Y5N1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7564337 0.98 TDP1 (0.58) TDP1EYA2APPACELMNA
SCHEMBL2799777 0.98 TDP1 (0.52) TDP1EYA2APPACELMNA
SCHEMBL12243695 0.96 TDP1 (0.56) TDP1EYA2APPACELMNA
SCHEMBL2807141 0.96 TDP1 (0.56) TDP1EYA2APPACELMNA
SCHEMBL212272 0.92 AKR1B1 (0.52) TDP1EYA2APPACELMNA
SCHEMBL186172 0.90 MEP1B (0.50) TDP1LMNAHDAC3HDAC1HDAC2
SCHEMBL3132717 0.89 HTT (0.53) LMNAKDM4EALOX15TSHRCYP2C19
SCHEMBL3256423 0.89 HDAC3 (0.45) TDP1EYA2APPACELMNA
SCHEMBL27541878 0.89 OPRK1 (0.56) TDP1CYP2C19ADRA1ASLC6A3HDAC3
SCHEMBL12222172 0.88 CALM1 (0.52) TDP1EYA2APPACELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822390-B2 Scale inhibitor CLARIANT FINANCE (BVI) LIMITED (VG) 2014-09-02 — — US claimed
EP-2556130-A1 SCALE INHIBITOR Clariant Finance (BVI) Limited (VG) 2013-02-13 — — EP claimed
EP-2371923-B1 Scale inhibitor CLARIANT FINANCE BVI LTD (VG) 2013-02-13 — — EP claimed
US-20130023449-A1 Scale Inhibitor CLARIANT FINANCE (BVI) LIMITED (VG) 2013-01-24 — — US claimed
WO-2011120655-A1 SCALE INHIBITOR CLARIANT INTERNATIONAL LTD (CH) 2011-10-06 — — WO claimed
EP-2371923-A1 Scale inhibitor Clariant International Ltd. (CH) 2011-10-05 — — EP claimed
US-4285575-A USING AN ELECTROCHROMIC ELECTROLYTE CONTAINING A CARBOXYLIC-CONTAINING COMPLEXING AGENT, A FERROUS SALT, A METAL SALT, AND A CHROMOGEN; DURABILITY CANON KABUSHIKI KAISHA (JP) 1981-08-25 — — US claimed
US-4212518-A ELECTROCHROMIC CELL CANON KABUSHIKI KAISHA (JP) 1980-07-15 — — US claimed
US-11420910-B2 Methods for low temperature fluorine-18 radiolabeling of biomolecules KATHOLIEKE UNIVERSITET LEUVEN (BE) 2022-08-23 — — US disclosed
EP-3434253-B1 DENTAL ALGINATE IMPRESSION MATERIAL G C DENTAL IND CORP (JP) 2022-02-02 — — EP disclosed
EP-3212610-B1 METHODS FOR LOW TEMPERATURE FLUORINE-18 RADIOLABELING OF BIOMOLECULES UNIV LEUVEN KATH (BE) 2020-10-28 — — EP disclosed
US-10744071-B2 Dental alginate impression material GC CORPORATION (JP) 2020-08-18 — — US disclosed
US-20190076336-A1 DENTAL ALGINATE IMPRESSION MATERIAL GC CORPORATION (JP) 2019-03-14 — — US disclosed
EP-3434253-A1 ALGINATE IMPRESSION MATERIAL FOR DENTAL USE GC Corporation (JP) 2019-01-30 — — EP disclosed
US-4285575-A USING AN ELECTROCHROMIC ELECTROLYTE CONTAINING A CARBOXYLIC-CONTAINING COMPLEXING AGENT, A FERROUS SALT, A METAL SALT, AND A CHROMOGEN; DURABILITY CANON KABUSHIKI KAISHA (JP) 1981-08-25 — — US disclosed
US-4212518-A ELECTROCHROMIC CELL CANON KABUSHIKI KAISHA (JP) 1980-07-15 — — US disclosed
US-4142061-A FOR STABILIZING COBALT CABONYL CATALYST CHEVRON RESEARCH COMPANY (US) 1979-02-27 — — US disclosed
US-4096191-A Hydroformylation of olefins using azoxy-dentated ligands CHEVRON RESEARCH COMPANY (US) 1978-06-20 — — US disclosed
US-4046879-A TOPICAL BOEHRINGER INGELHEIM GMBH (DT) 1977-09-06 — — US disclosed
US-3984477-A MOLYBDENUM, BISMUTH, IRON, NICKEL AND COBALT DAICEL, LTD. (JA) 1976-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420910-B2 Methods for low temperature fluorine-18 radiolabeling of biomolecules H1-3, H1-0, H1-2 TDP1 4426/4885EYA2 2357/4885APP 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback